Navigating the Complex Landscape of US Supplement Regulation: A Mid-Year Update
As we approach the halfway point of 2026, the US supplement industry finds itself at a pivotal moment, navigating a complex web of regulatory updates and evolving compliance strategies. While no single event has fundamentally altered the regulatory landscape, the cumulative effect of various initiatives is prompting companies to reassess their approaches and consider the broader implications for the future of the industry.
The Human Foods Program's Priorities: A Shifting Focus
One of the most significant developments is the Human Foods Program (HFP) at the U.S. Food and Drug Administration (FDA) publishing its updated 2026 priorities. The HFP's roadmap emphasizes stronger risk-based enforcement, modernization initiatives, and the implementation of broader food safety priorities. The Office of Dietary Supplement Programs (ODSP) now sits within the newly established Office of Food Chemical Safety, Dietary Supplements & Innovation, positioning dietary supplements within one of the HFP's three core risk pillars: food chemical safety, nutrition, and microbiological food safety.
This shift in focus has important implications for the industry. By emphasizing risk-based enforcement and modernization, the FDA is sending a clear message that it is taking a more proactive approach to regulating the supplement sector. Companies will need to be more vigilant in their compliance efforts and consider the broader regulatory environment when developing their strategies.
Closing the GRAS Loophole: A Major Regulatory Priority
One of the most high-profile regulatory priorities for the HFP is revisiting Generally Recognized as Safe (GRAS) substances. The FDA is taking steps to close what it describes as the “GRAS loophole,” which allows companies to self-determine that an ingredient is GRAS and market it without notifying the agency. This loophole has been a source of concern for the industry, as it can lead to a lack of transparency and oversight.
The proposed rule, tentatively scheduled to be published in December 2026, would require mandatory GRAS notices for certain human and animal food substances. This could increase FDA scrutiny of novel ingredients, raise compliance costs and timelines, and influence ingredient innovation strategies. For companies marketing ingredients across both conventional food and supplement sectors, the mandatory GRAS notification system could provide greater regulatory transparency.
Exploring the Scope of Dietary Substances: A Close Watch
The FDA's public meeting regarding the scope of permissible dietary ingredients continues to be one of the most closely watched developments. The discussion focuses on whether the FDA should modernize its interpretation of dietary ingredients to keep pace with scientific and technological advancements like precision fermentation, cell culture technology, and recombinant production. This is a critical issue, as it could impact the development and marketing of novel ingredients.
The identity of notable supplement ingredients like proteins, enzymes, and microorganisms not specifically listed in section 201(ff)(1) of the Food Drug, and Cosmetic Act is also under consideration. This raises important questions about the definition of a “dietary ingredient” and the boundaries of the supplement industry.
Expanding State Regulation: A Fragmented Compliance Environment
State policymakers continue to shape the regulatory landscape for dietary supplements through legislation, enforcement actions, and environmental initiatives. This has created an increasingly fragmented compliance environment, representing a greater day-to-day compliance burden for companies navigating a patchwork of state regulations. States are also taking the lead in addressing the federal “GRAS loophole” by implementing strict disclosure databases and ingredient bans that promote greater transparency and strengthen safety oversight.
While these initiatives focus primarily on conventional food additives rather than dietary supplements, they reflect a broader trend of states filling regulatory gaps where federal oversight is perceived as lagging. This trend could have significant implications for the industry, as it may lead to a more complex and fragmented compliance environment.
Congressional Proposals: A Focus on Oversight and Consumer Access
Congressional action focused on three main pieces of legislation, all of which remain in the committee stage. The reintroduction of the Dietary Supplement Listing Act of 2026 is particularly significant, as it is Senator Dick Durbin’s third legislative attempt to secure a federal registry. Durbin asserts that the absence of a provision requiring companies to register their products with the FDA has left the agency without the information needed to properly understand or oversee a market that has grown from 4,000 to an estimated 100,000 products over the last 30 years.
The debate between increased federal oversight, state regulation, and consumer access is at the heart of these proposals. The outcome of this debate will have significant implications for the industry, as it could shape the future of supplement regulation and the balance of power between federal and state authorities.
FTC Health Claims Enforcement: A Focus on Substantiation
Federal Trade Commission (FTC) enforcement activity in the first half of the year has reaffirmed the agency’s continued focus on substantiating consumer-facing claims with competent and reliable evidence. Areas drawing the greatest scrutiny remain weight loss and body composition claims, performance and cognitive benefit claims, influencer marketing, and broad “natural,” purity, and sustainability positioning.
One headline-grabbing enforcement action saw the FTC sue multilevel marketer Amare Global and its principals for allegedly misrepresenting that its supplements could treat or cure health conditions such as depression, anxiety, and ADHD. This action highlights the FTC’s commitment to holding companies accountable for making false or misleading claims.
Private Litigation: A Growing Risk for Companies
Beyond regulation or enforcement at any level, private litigation remains one of the industry’s fastest-growing risks. Plaintiffs are increasingly relying on state consumer protection statutes, false advertising laws, and unjust enrichment theories. Even companies with strong compliance records remain vulnerable to consumer litigation.
This trend underscores the importance of companies taking a proactive approach to compliance and risk management. By staying ahead of the curve and being prepared for potential legal challenges, companies can mitigate the impact of private litigation and protect their interests.
Conclusion: Navigating the Complex Landscape
As we approach the end of the first half of 2026, the US supplement industry finds itself at a critical juncture. The cumulative effect of regulatory updates and evolving compliance strategies is prompting companies to reassess their approaches and consider the broader implications for the future of the industry. The HFP's priorities, the GRAS loophole, the scope of dietary substances, state regulation, congressional proposals, and FTC health claims enforcement are all key areas of focus for companies navigating this complex landscape.
In my opinion, the most significant development is the FDA's emphasis on risk-based enforcement and modernization. This shift in focus signals a more proactive approach to regulating the supplement sector, and companies will need to be prepared to adapt their strategies to this new environment. As we move forward, it will be crucial for companies to stay informed about regulatory developments and take a proactive approach to compliance and risk management. The future of the US supplement industry depends on its ability to navigate this complex landscape successfully.
